



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b>  <b>A61K 31/66</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/51244</b>  <b>(43) International Publication Date:</b> 14 October 1999 (14.10.99)
<b>(21) International Application Number:</b> PCT/GB98/03540  <b>(22) International Filing Date:</b> 26 November 1998 (26.11.98)  <b>(30) Priority Data:</b> 9807298.6                      3 April 1998 (03.04.98)                      GB  <b>(71) Applicant (for all designated States except US):</b> BRITANNIA PHARMACEUTICALS LIMITED [GB/GB]; 41/51 Brighton Road, Redhill, Surrey RH1 5TS (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HILLS, Brian, Andrew [AU/AU]; 44 Bowsprit Parade, Cleveland, QLD 4163 (AU). WOODCOCK, Derek, Alan [GB/GB]; 24 Shrublands Road, Berkhamstead, Hertfordshire HP4 3HX (GB).  <b>(74) Agent:</b> WOODCRAFT, David, Charles; Brookes & Martin, High Holborn House, 52/54 High Holborn, London WC1V 6SE (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> USE OF PHOSPHOLIPIDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION OF ADHESIONS		
<b>(57) Abstract</b>  A medicament is disclosed for reducing the probability of surgical adhesions. The medicament comprises a surface active phospholipid which is capable of binding to mesothelial membranes and is applied as a dry powder or dispersion in saline to the wound site.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## USE OF PHOSPHOLIPIDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION OF ADHESIONS

This invention relates to medicaments for and methods of reducing the probability of surgical adhesions.

Following surgery, membranes which have been severed may 'cross-heal'. For example the abdominal wall can heal with the peritoneum and adhere to it. This is known as an adhesion. A very serious complication of adhesions inside the peritoneum is intestinal obstruction. Unless corrected surgically this can rapidly be fatal. It has been estimated that in the US in 1988 the cost of correcting lower abdominal pelvic adhesions was of the order of US\$ 1180 million (AH De Cherney and GS diZeregram Surgical Clinics of North America 77(3), 671). Attempts have been made to reduce adhesions by providing physical barriers such as sheets of hyaluronic acid and carboxymethylcellulose. While providing an initial barrier the sheets degrade.

It has now been unexpectedly found that natural occurring surface active phospholipids and enantiomers thereof can substantially reduce the likelihood of adhesions forming.

According to the invention there is provided a method of reducing the probability of surgical adhesion comprising administering SAPL to mesothelial membranes during surgery.

According to the invention there is provided the use of a SAPL in the manufacture of a medicament for use in reducing the probability of surgical adhesions following surgery.

Embodiments of the invention will be described by way of non-limiting example by reference to the Figure which shows the length of adhesion formed under various conditions.

A physical or chemical binding of the surfactant to the membrane is highly desirable. Examples of suitable phospholipids include diacyl phosphatidyl cholines (DAPC's) such as dipalmitoyl phosphatidyl choline (DPPC), dioleoyl phosphatidyl

choline (DOPC) and distearyl phosphatidyl choline (DSPC). It is also preferred to include a spreading agent in the composition to assist the DPPC or analogous compound rapidly to form a thin film over the surface of the membrane. A number of agents are capable of acting in this way including other phospholipids, such as phosphatidylglycerols (PG); phosphatidylethanolamines (PE); phosphatidylserines (PS) and phosphatidylinositols (PI). Another useful spreading agent is cholesteryl palmitate (CP). We prefer to use dipalmitoyl phosphatidyl choline (DPPC) and unsaturated phosphatidyl glycerol (PG) either alone or in combination. A mixture comprising DPPC 70 wt% and PG 30 wt% can be used. This material is commercially available as ALEC™ from Britannia Pharmaceutical Limited. ALEC is known for use in treating respiratory distress syndrome see for example British Medical Journal 294 (1984) 991-996.

A widely accepted theory on the mechanism of action of ALEC in the lungs of neonates is that it functions principally by lowering surface tension. Since there is no air-water interface in the normal peritoneal cavity one would not expect ALEC and other SAPL's to be effective in preventing the formation of or reduction the probability of forming adhesions. It has however been experimentally found that SAPL's do, in fact reduce the frequency of adhesion formation as will become apparent from the experimental data set forth below.

40 rabbits were taken. A surgical opening was made in the peritoneum. Opposing peritoneal surfaces were subjected to a sterilised 50 mm abrasion. In 10 cases the opening was simply closed. In a further 10 cases the abrasion was perfused with dialysate prior to closure. In a still further 10 cases the abrasion was perfused with a suspension of ALEC in dialysate and the opening closed. In a final 10 cases powdered ALEC was blown into the abrasion prior to closure. Following healing the peritoneum was reopened and the presence of adhesions noted. Where adhesions were noted their length was measured. The results are shown in Table 1.

Table 1

	Control	Dialysate	ALEC & Dialysate	ALEC
Number of adhesion free cases	1	5	4	5
Total length of adhesion (mm)	320	197	151	91
Reduction in adhesion length relative to control	-	38%	53%	72%
Mean Adhesive Length (mm)	32	19.7	15.1	9.1
Standard Deviation	5	10.5	9	5

One can say therefore with a high degree of confidence (even with a very limited number of samples) that ALEC powder markedly reduces both the likelihood of adhesion formation and the length of the adhesions which do form. There is also evidence that a suspension of ALEC is more effective than either no treatment or treatment with dialysate.

Preferably the SAPL is used in the form of a dry powder aerial dispersion.

Phosphatidyl glycerol (PG) is believed to be capable of binding to the surface of the animal tissue and is, therefore, a preferred component of the SAPL. Dipalmitoyl phosphatidyl choline (DPPC) may function also in this way and is also a preferred compound of the SAPL. PG has a further important function in

medicaments employed in the present invention which is its ability to cause the DPPC to form a dry powder. The particle size of such powders is not critical and the controlling factor is that the size is preferably such that medicament can be readily instilled into the surgical site. Generally, the particle size is within the range of 0.5 to 100 $\mu$ m. Particles which are more readily conveyed in a gas stream have a particle size of from 0.5 to 20 $\mu$ m, preferably 0.5 to 10 $\mu$ m and more preferably 0.5 to 2 $\mu$ m. Finely-divided dry powders of this kind are believed to be absorbed very rapidly onto the surfaces of mesothelial membranes, i.e. bound to the epithelium. Preferably, the SAPL compositions employed in the present invention are blends of dipalmitoyl phosphatidyl choline (DPPC) and PG, although as indicated above, other phospholipids may be employed.

The medicament should generally be essentially free from animal protein in order to avoid the danger of patient sensitivity to animal proteins. Also, animal proteins may become adhesive and, for this reason, should preferably be excluded from the compositions.

DPPC is commercially available from Sigma Chemical Co. Ltd. or can be prepared synthetically by the use of acyl chlorides using the method of Baer & Bachrea - Can. J. Of Biochem. Physiol 1959; 37, page 953 and is available commercially from Sigma (London) Ltd. The PG may be prepared from egg phosphatidyl choline by the methods of Cornfurions et al and Dawson, Biochem. Biophys Acta 1977; 488; pages 36-42 and Biochem J. 1947; 192; pages 205-210.

The medicaments employed in the present invention are generally finely-divided dry powders having a particle size distribution which is small enough to be introduced into the surgical site in a gas stream from a dispersion device. The material available commercially as 'Alec' has a particle size distribution such that a major proportion is between 0.5 and 2 $\mu$ m with a median particle diameter of about 1.2  $\mu$ m. However, as mentioned above, larger particle size powders can be satisfactorily used in accordance with the invention. The medicament of the present invention may be introduced into the surgical site through a cannula, e.g. connected to a syringe.

However, we prefer to employ a dispersion device which utilises a propellant. These may employ a propellant such as a halocarbon to form a gas stream and may include a tapered discharge nozzle, baffle or venturi to accelerate particles through a discharge nozzle. Suitable halocarbons include hydrofluorocarbons, hydrofluorochlorocarbons and fluorochlorocarbons having a low boiling point, such as those marketed by DuPont under the trade marks "Freon" and "SUVA". Pharmaceutically acceptable hydrofluoroalkanes are available as HFA-134a and 227.

One suitable design of dispensing device for administering the powdered material to a surgical site is shown in Figures 2 and 3 in which:-

Figure 2 is a side elevation of the dispenser; and

Figure 3 is a similar view, but shows its interior.

Referring to Figures 2 and 3, a casing (10) is formed from two plastic mouldings (12 & 13) which snap together to form a container for a pressurised canister (14) and a vial (15). Canister (14) contains a low boiling liquid, preferably a hydrofluorocarbon such as HFA-134a or HFC-227, under sufficient pressure to maintain the propellant liquid at normal room temperature. Vial (15) contains the powdered medicament, such as "Alec". Canister (14) has a release valve (16) which is received in a recess (17) so that finger pressure on the inverted end (18) of the canister will cause propellant to be released into a tube (19). Tube (19) is typically a hard plastics, e.g. pvc or polypropylene, tube of about 2-3 mm outside diameter and about 0.5 to 2 mm inside diameter. Tube (19) connects valve (16) with a fitting (20) and thence to a tube or needle (21) which extends into the vial (15). Vial (15) may be closed with a rubber seal which is penetrated by the tube or needle (21) and self-seals around the tube or needle. A second needle or tube (22) extends part way into the vial through the rubber seal in the neck of the vial and connects with a fitting (23). Fitting (23) discharges into a catheter (4) from which the powder can be directed to the desired area of the surgical site. The advantage of the dispenser shown in Figures 2 and 3 is that it can be operated 'one-handed' while the doctor or nurse ensures that the catheter is correctly positioned to distribute powder into the surgical site. A

catheter may not be necessary. The powder may simply be sprayed onto the area of the surgical wound.

In general, the DPPC and PG may be present in a weight ratio of from 9:1 to 1:9. Compositions employed in current formulations have been in the weight ratio of from about 6:4 to 8:2.

It is desirable that the SAPL (or its active component) should not break down rapidly in the environment of the surgical wound. One of the factors which will reduce the life of a release lining or coating will be the presence of enzymes capable of digesting DPPC and/or PG. Such enzymes only attack the laevo rotatory (L) form, which constitutes the naturally occurring form. Therefore, the anti-adhesion medicament should preferably contain the dextro rotatory (D form) or at least comprise a racemic mixture which is obtained by synthetic preparation routes. This also applies to the other SAPL/s mentioned above.

As an alternative to use as a powder dispersion, the medicament may be used as a dispersion in an inert liquid, for example, in sterile saline, preferably isotonic saline, which is approximately 0.9% aqueous sodium chloride.

The SAPL may comprise phosphatidyl glycerol (PG) either alone or in admixture with other components. PG has a useful additional function of forming very finely divided dispersions.

The SAPL may comprise dipalmitoyl phosphatidyl choline (DPPC) either alone or in admixture with other components such as PG.

In preferred embodiments the medicament is essentially free of animal protein to avoid patient sensitivity and also to aid the formation of finely divided particle.

When PG and DPPC are co-precipitated from a common solvent a fine powder is formed. At a weight ratio DPPC: PG of about 7:3 the mixture spreads rapidly at body temperature.

In general the weight ratio DPPC:PG lies in the range 9:1 to 1:9 preferably 6:4 to 8:2.

It may be advantageous to include other active substances into the medicament, such as anti-fungal or anti-bacterial agents.

**CLAIMS**

1. The use of surface active phospholipids (SAPL) in the manufacture of a medicament for use in reducing the probability of adhesions following surgery.
2. A use as claimed in claim 1 wherein the SAPL is selected to bind to tissue at a surgical site.
3. A use as claimed in claim 1 or claim 2 wherein the SAPL is in powder form.
4. A use as claimed in claim 1 or claim 2 wherein the SAPL is a dispersion in aqueous saline.
5. A use as claimed in any one of the preceding claims wherein the SAPL comprises dipalmitoylphosphatidyl choline (DPPC).
6. A use as claimed in any one of the preceding claims wherein the SAPL comprises unsaturated phosphatidyl glycerol (PG).
7. A use as claimed in claim 5 wherein the SAPL comprises a mixture of DPPC and PG at a weight ratio of 1:9 to 9:1.
8. A use as claimed in claim 7 wherein the weight ratio of DPPC : PG is 6:4 to 8:2.

STUDY OF SURGICAL ADHESIONS IN 40 RABITS




Fig.1




Fig. 2




Fig. 3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/03540

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 12026 A (MACNAUGHT PTY LTD) 22 August 1991	1,2
Y	see abstract see page 3 - page 6	3-8
X	M.SNOJ ET AL.: "Effect of phosphatidylcholine on postoperative adhesions after small bowel anastomosis in the rat" BR J SURG, vol. 79, no. 5, 1992, pages 427-429, XP002098866	1,2
Y	see abstract	3-8
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 April 1999

Date of mailing of the international search report

20/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Tzschoppe, D

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 98/03540

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AAMER AR'RAJAB ET AL.: "Phosphatidylcholine prevents postoperative adhesions: An experimental study in the rat" J SURG RES, vol. 50, no. 3, 1991, pages 212-215, XP002098867	1,2
Y	see abstract	3-8
Y	EP 0 528 034 A (TOKYO TANABE CO) 24 February 1993 see page 2 - page 3	3-8
P,X	WO 98 53800 A (APPLIED BIOTECHNOLOGY INC ;KOROLY MICHAEL V (US)) 3 December 1998 see claims 1-46	1,2

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 98/03540

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9112026	A	22-08-1991	NONE	
EP 0528034	A	24-02-1993	AU 660612 B	06-07-1995
			AU 7857191 A	10-12-1991
			WO 9117766 A	28-11-1991
WO 9853800	A	03-12-1998	AU 7685798 A	30-12-1998